AMRX vs SO · P/E 44, rev $2.79B vs P/E 22, rev $29.55B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Southern Company (SO) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Southern Company (SO) is a utilities - regulated electric company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported SO revenue for 2025-12-31 was $29.55B. Net income was $4.34B. Revenue was up 10.6% from 2024-12-31 to 2025-12-31. SO currently screens at market cap $101.55B and trailing P/E 22.1.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. SO currently screens at market cap $101.55B and trailing P/E 22.1.
Not investment advice. Open the AMRX and SO stock pages for the full models.
Not investment advice.